Sandoz buys 10 biosimilars from Henlius in $322M deal
What's the deal? SandozDealroom has a profile for this one. Try Dealroom → has agreed to acquire 10 biosimilar products from China's Henlius in a deal worth $322 million. The transaction expands the Swiss generics maker's biosimilars pipeline.
What each side does: Sandoz, spun off from NovartisDealroom has a profile for this one. Try Dealroom → in 2023, is a leading maker of generic and biosimilar medicines. Henlius is a Chinese biopharmaceutical company that develops and manufactures biosimilars.
Why now? Biosimilars — cheaper copies of biologic drugs — are drawing intense investment as blockbuster biologics lose patent protection. Building out a deep pipeline positions Sandoz to capture that demand.
What's the endgame? The deal reinforces Sandoz's strategy to lead the biosimilars market, adding scale to its portfolio through an established Chinese partner.
The signal: The acquisition underscores growing consolidation in biosimilars, with Western drugmakers increasingly sourcing pipelines from Chinese developers to meet demand for lower-cost biologics.
Read more: Rama on Healthcare
Image credit: Generated with Gemini
